Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 38 min ago
Peer-reviewedLicence not statedClinical cancer research : an official journal of the American Association for Cancer Research

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.

  • Jules L Derks
  • Noémie Leblay
  • Erik Thunnissen
  • Robert Jan Van Suylen
  • Michael Den Bakker
  • Harry J M Groen
  • Egbert F Smit
  • Ronald Damhuis
  • Esther C van Den Broek
  • Amélie Charbrier
  • Matthieu Foll
  • James D Mckay
3 more authors
  • Lynnette Fernandez-Cuesta
  • Ernst-Jan M Speel
  • Anne-Marie C Dingemans
Open at sourcePDFDOICite

Related

  1. Clinical and Demographic Characteristics of Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma: A Single-Center Experience
    Yeşim Özufacık Bölükbaşı, Aydın Aytekin
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Case Report: Third-line QL1706, a bifunctional PD-1/CTLA-4 MabPair product, plus chemotherapy for primary small-cell neuroendocrine carcinoma of the ureter
    Xiaomin Li, Zhe Meng, Yao Liu +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyFrontiersCrossrefDOAJ
  3. First-Line Lorlatinib for ALK-Rearranged Pulmonary Large-Cell Neuroendocrine Carcinoma with Brain Metastases and Suspected Leptomeningeal Involvement: A Case Report and Literature Review
    Yoshio Nakano, Kazuya Nishimura, Hiroka Serizawa +5
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  4. Molecular characterization of large cell neuroendocrine carcinoma of the lung by multilayered omics analysis
    Megumi Tateishi, Yoshiki Otsuka, Ryota Matsuoka +17
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  5. Favorable Response to Chemotherapy with Durvalumab Plus Tremelimumab in Two Cases of KRAS G12C-positive Pulmonary Sarcomatoid Carcinoma
    Takeru Ichikawa, Kenichiro Kudo, Yuki Takigawa +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{derks2026molecular,
  title = {{Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.}},
  author = {Jules L Derks and Noémie Leblay and Erik Thunnissen and Robert Jan Van Suylen and Michael Den Bakker and Harry J M Groen and Egbert F Smit and Ronald Damhuis and Esther C van Den Broek and Amélie Charbrier and Matthieu Foll and James D Mckay and Lynnette Fernandez-Cuesta and Ernst-Jan M Speel and Anne-Marie C Dingemans},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  year = {2026},
  month = oct,
  doi = {10.1158/1078-0432.ccr-17-1921},
  url = {https://hal.science/hal-05842971v1},
}
RIS
TY  - JOUR
TI  - Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
AU  - Jules L Derks
AU  - Noémie Leblay
AU  - Erik Thunnissen
AU  - Robert Jan Van Suylen
AU  - Michael Den Bakker
AU  - Harry J M Groen
AU  - Egbert F Smit
AU  - Ronald Damhuis
AU  - Esther C van Den Broek
AU  - Amélie Charbrier
AU  - Matthieu Foll
AU  - James D Mckay
AU  - Lynnette Fernandez-Cuesta
AU  - Ernst-Jan M Speel
AU  - Anne-Marie C Dingemans
PY  - 2026
DA  - 2026/10/28
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-17-1921
UR  - https://hal.science/hal-05842971v1
ER  -